Regulatory factor | Dose of ambroxol mg·kg−1·day−1 | Days after virus infection | |||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
Trypsin-like protease activity µU·mL−1 | 0 | 25.0±2.0 | 25.0±1.8 | 20.0±1.5 | 20.0±5.0 | 25.0±6.0 | 25.0±8.0 | 20.0±10.0 | 25.0±8.0 |
10 | 26.7±3.0 | 30.0±10.0 | 33.4±1.6* | 55.0±16.0* | 50.0±13.0* | 20.0±9.1 | 25.0±10.0 | ||
30 | 26.7±2.4 | 33.4±18.0 | 40.0±11.0* | 60.0±22.0* | 25.0±10.0 | 20.0±7.7 | 20.0±6.0 | ||
SP-A ng·mL−1 | 0 | 2.2±0.3 | 2.4±0.8 | 2.7±1.1 | 2.4±1.0 | 2.7±0.9 | 2.3±0.7 | 2.7±0.8 | 2.5±1.0 |
10 | 3.0±0.9 | 3.4±1.1 | 4.3±2.2 | 5.6±1.4* | 6.8±3.0* | 6.2±2.2* | 7.4±3.1* | ||
30 | 3.9±1.7 | 5.2±1.0* | 5.6±1.9* | 8.3±1.2* | 7.2±3.1* | 6.9±2.8* | 6.6±2.1* | ||
MPI µU·mL−1 | 0 | 112.5±30.0 | 125.0±26.0 | 130.0±50.0 | 167.0±40.0 | 200.0±98.0 | 130.0±32.0 | 200.0±50.0 | 165.0±50.0 |
10 | 150.0±40.0 | 200.0±50.0 | 250.0±60.0 | 300.0±50.0 | 500.0±70.0* | 470.8±50.0* | 430.0±100.0* | ||
30 | 200.0±60.0 | 250.0±70.0 | 458.5±60.0* | 550.0±80.0* | 500.0±60.0* | 250.0±80.0 | 167.0±70.0 |
The data are presented as means±sd unless otherwise stated, (n=5) at each time point
*: p<0.05 between control and ambroxol